TrkA alternative splicing-Reference-Cited by-同舟云学术

TrkA alternative splicing

Published:2004-10 Issue:4 Volume:6 Page:347-360
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Tacconelli Antonella,Farina Antonietta R.,Cappabianca Lucia,DeSantis Giuseppina,Tessitore Alessandra,Vetuschi Antonella,Sferra Roberta,Rucci Nadia,Argenti Beatrice,Screpanti Isabella,Gulino Alberto,Mackay Andrew R.

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference70 articles.

1. TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor;Arevalo;Mol. Cell. Biol,2000

2. A novel mutation within the extracellular domain of TrkA causes constitutive receptor activation;Arevalo;Oncogene,2001

3. Multiple defects of the nerve growth factor receptor in human neuroblastomas;Azar;Cell Growth Differ,1990

4. Neuroendocrine tumours;Barakat;Endocr. Relat. Cancer,2004

5. Tissue specific alternative splicing generates two isoforms of the TrkA receptor;Barker;J. Biol. Chem,1993

Cited by 171 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib;Acta Pharmaceutica Sinica B;2024-02

2. MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression;Oncogene;2023-12-04

3. NTRK1-mediated protection against manganese-induced neurotoxicity and cell apoptosis via IGF2 in SH-SY5Y cells;Biomedicine & Pharmacotherapy;2023-12

4. Neuroblastoma Interaction with the Tumour Microenvironment and Its Implications for Treatment and Disease Progression;Current Oncology;2023-10-15

5. Characterization of the folding and binding properties of the PTB domain of FRS2 with phosphorylated and unphosphorylated ligands;Archives of Biochemistry and Biophysics;2023-09